TKAI Insider Trading Activity and SEC Form 4 Filings
TKAI insider trading summary
No open-market insider purchases or sales of Tokai Pharmaceuticals Inc (TKAI) have been reported on SEC Form 4 in the past 12 months.
Latest TKAI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 15, 2016 | Stephen Buckley Jr. | Insider | Buy | $46K (8,000 @ $5.74) |
| Nov 11, 2015 | Stephen Buckley Jr. | Insider | Buy | $34K (3,000 @ $11.25) |
| Sep 21, 2015 | John S. McBride | Chief Operating Officer | Sell | $189K (13,500 @ $14.01) |
| Sep 8, 2015 | Lee Kalowski | Chief Financial Officer | Sell | $61K (4,668 @ $13.13) |
| Sep 2, 2015 | Lee Kalowski | Chief Financial Officer | Sell | $28K (2,158 @ $12.96) |
| Jul 29, 2015 | Jodie Pope Morrison | President and CEO | Sell | $8K (564 @ $13.70) |
| Jul 28, 2015 | Jodie Pope Morrison | President and CEO | Sell | $164K (12,000 @ $13.70) |
| Jul 15, 2015 | Novartis Bioventures Ltd | 10% Owner | Sell | $51K (3,566 @ $14.26) |
| Jul 15, 2015 | AG Novartis | 10% Owner | Sell | $51K (3,566 @ $14.26) |
| Jul 14, 2015 | AG Novartis | 10% Owner | Sell | $401K (27,861 @ $14.41) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.